NCT06956157View on ClinicalTrials.gov

NAC for Treatment-Resistant OCD and Other Related Disorders

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 22, 2022

Primary Completion Date

November 13, 2024

Study Completion Date

November 13, 2025

Conditions
Obsessive Compulsive Disorder (OCD)
Interventions
DRUG

N-Acetylcysteine Tablets

In addition to participants' existing medication regimens, NAC will be added.

DRUG

Placebo Oral Tablet

Placebo oral tablets are identical in appearance (size, shape, color), packaging, taste, and administration schedule to the N-Acetylcysteine tablets to maintain blinding. The tablets contain inert excipients and no active pharmacological ingredients.

Trial Locations (1)

510120

Guangdong Mental Health Center, Guangdong Provincial People's Hospital, GuangDong

All Listed Sponsors
lead

Guangdong Provincial People's Hospital

OTHER

NCT06956157 - NAC for Treatment-Resistant OCD and Other Related Disorders | Biotech Hunter | Biotech Hunter